FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911249025> ?p ?o ?g. }

• W2911249025 endingPage "623" @default.
• W2911249025 startingPage "607" @default.
• W2911249025 abstract "Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, and most clinically curable patients are diagnosed with locally advanced disease. Although the efficacy of standard platinum-based chemotherapy doublets is relatively limited. The effect of immune checkpoint inhibitors (ICIs) remains controversial, and its role in the first-line treatment of advanced NSCLC is obscure. Thus, we carried out a systematic review and meta-analysis to compare the efficacy and safety of ICIs for advanced NSCLC.The PubMed, Cochrane Central Register Trial, and American Society of Clinical Oncology databases were searched from inception to 30 April 2018. We searched for randomized controlled trials comparing single-agent programmed cell death protein 1/programmed death-ligand 1 inhibitors (nivolumab, pembrolizumab, or atezolizumab) or cytotoxic T-lymphocyte-associated antigen 4 inhibitor (ipilimumab) with chemotherapy in NSCLC patients. Progression-free survival, overall survival, objective response rate, and adverse events were pooled for meta-analysis by Review Manager (RevMan version 5.3) software.After exclusion of ineligible studies, 12 eligible randomized controlled trials were included. Data showed that ICIs significantly improved progression-free survival (HR 0.66, 95% CI 0.57-0.77, P < 0.00001), overall survival (HR 0.77, 95% CI 0.64-0.91, P = 0.003), and but not objective response rate (RR 1.97, 95% CI 1.25-3.13, P = 0.004) in all unselected NSCLC populations. However, they failed to increase the OS of programmed death-ligand 1 = 1-49% subgroup (HR 0.78, 95% CI 0.51-1.19, P = 0.25) and PFS of programmed death-ligand 1<1% subgroup (HR 0.85; 95%CI 0.70 to 1.03, P=0.09) in ICIs+chemotherapy over chemotherapy. Meanwhile, OS of programmed death-ligand =1-49% subgroup (HR 0.92; 95%CI 0.77 to 1.10, P=0.36) and PFS of programmed death-ligand 1≥50% subgroup (HR 0.76; 95%CI 0.52 to 1.11, P=0.15) showed no significant differences in ICIs over chemotherapy. Furthermore, fewer adverse events were observed in the ICIs groups than control groups.ICIs are overall better tolerated than chemotherapy. Our results provide further evidence supporting the favorable risk/benefit ratio for ICIs." @default.
• W2911249025 created "2019-02-21" @default.
• W2911249025 creator A5019120402 @default.
• W2911249025 creator A5053453125 @default.
• W2911249025 creator A5077001501 @default.
• W2911249025 creator A5080219816 @default.
• W2911249025 date "2019-02-07" @default.
• W2911249025 modified "2023-09-27" @default.
• W2911249025 title "Comparative efficacy and safety of first‐line treatments for advanced non‐small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta‐analysis" @default.
• W2911249025 cites W1617971067 @default.
• W2911249025 cites W1757407923 @default.
• W2911249025 cites W1990189227 @default.
• W2911249025 cites W1994993231 @default.
• W2911249025 cites W2009226744 @default.
• W2911249025 cites W2011941471 @default.
• W2911249025 cites W2016732129 @default.
• W2911249025 cites W2033672531 @default.
• W2911249025 cites W2048238388 @default.
• W2911249025 cites W2049553585 @default.
• W2911249025 cites W2059409197 @default.
• W2911249025 cites W2065409049 @default.
• W2911249025 cites W2066671159 @default.
• W2911249025 cites W2074546881 @default.
• W2911249025 cites W2094179246 @default.
• W2911249025 cites W2097383739 @default.
• W2911249025 cites W2098414192 @default.
• W2911249025 cites W2098923148 @default.
• W2911249025 cites W2104347254 @default.
• W2911249025 cites W2148367564 @default.
• W2911249025 cites W2156353875 @default.
• W2911249025 cites W2168598711 @default.
• W2911249025 cites W2198093519 @default.
• W2911249025 cites W2291298003 @default.
• W2911249025 cites W2293531514 @default.
• W2911249025 cites W2337836619 @default.
• W2911249025 cites W2340321058 @default.
• W2911249025 cites W2412037540 @default.
• W2911249025 cites W2509718788 @default.
• W2911249025 cites W2522296004 @default.
• W2911249025 cites W2522337762 @default.
• W2911249025 cites W2526413681 @default.
• W2911249025 cites W2526607882 @default.
• W2911249025 cites W2527905628 @default.
• W2911249025 cites W2529904548 @default.
• W2911249025 cites W2560322684 @default.
• W2911249025 cites W2560367415 @default.
• W2911249025 cites W2563204578 @default.
• W2911249025 cites W2567564314 @default.
• W2911249025 cites W2572174216 @default.
• W2911249025 cites W2588681363 @default.
• W2911249025 cites W2635951006 @default.
• W2911249025 cites W2753529762 @default.
• W2911249025 cites W2796582438 @default.
• W2911249025 cites W2797675588 @default.
• W2911249025 cites W2805354595 @default.
• W2911249025 cites W2806145489 @default.
• W2911249025 cites W2806388842 @default.
• W2911249025 cites W2807431877 @default.
• W2911249025 cites W2888059202 @default.
• W2911249025 cites W2892009523 @default.
• W2911249025 cites W2892128081 @default.
• W2911249025 doi "https://doi.org/10.1111/1759-7714.12971" @default.
• W2911249025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6449246" @default.
• W2911249025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30734504" @default.
• W2911249025 hasPublicationYear "2019" @default.
• W2911249025 type Work @default.
• W2911249025 sameAs 2911249025 @default.
• W2911249025 citedByCount "20" @default.
• W2911249025 countsByYear W29112490252019 @default.
• W2911249025 countsByYear W29112490252020 @default.
• W2911249025 countsByYear W29112490252021 @default.
• W2911249025 countsByYear W29112490252022 @default.
• W2911249025 countsByYear W29112490252023 @default.
• W2911249025 crossrefType "journal-article" @default.
• W2911249025 hasAuthorship W2911249025A5019120402 @default.
• W2911249025 hasAuthorship W2911249025A5053453125 @default.
• W2911249025 hasAuthorship W2911249025A5077001501 @default.
• W2911249025 hasAuthorship W2911249025A5080219816 @default.
• W2911249025 hasBestOaLocation W29112490251 @default.
• W2911249025 hasConcept C121608353 @default.
• W2911249025 hasConcept C126322002 @default.
• W2911249025 hasConcept C143998085 @default.
• W2911249025 hasConcept C168563851 @default.
• W2911249025 hasConcept C197934379 @default.
• W2911249025 hasConcept C2775949291 @default.
• W2911249025 hasConcept C2776256026 @default.
• W2911249025 hasConcept C2777701055 @default.
• W2911249025 hasConcept C2780030458 @default.
• W2911249025 hasConcept C2780057760 @default.
• W2911249025 hasConcept C2781433595 @default.
• W2911249025 hasConcept C71924100 @default.
• W2911249025 hasConcept C95190672 @default.
• W2911249025 hasConceptScore W2911249025C121608353 @default.
• W2911249025 hasConceptScore W2911249025C126322002 @default.
• W2911249025 hasConceptScore W2911249025C143998085 @default.
• W2911249025 hasConceptScore W2911249025C168563851 @default.
• W2911249025 hasConceptScore W2911249025C197934379 @default.
• W2911249025 hasConceptScore W2911249025C2775949291 @default.

• next